MTOR and fleck corneal dystrophy: MTOR (mechanistic target of rapamycin) inhibitors have emerged as a novel therapeutic option for targeting FCD-related seizures, as 60% of FCD II cases, particularly FCD IIb, display gene mutations in the mTOR signaling pathway [40].